Clinical trialNCT00528333CompletedPhase 2Interventional

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

SponsorSeagen Inc.Enrollment211Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Eric Sievers, MD
Seagen Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Southern Cancer Center
Mobile, Alabama, United States
Tower Cancer Research Foundation
Beverly Hills, California, United States
Glendale Memorial Hospital
Glendale, California, United States
Kenmar Research Institute
Los Angeles, California, United States
University of California Los Angeles
Los Angeles, California, United States
Bay Area Cancer Research Group
Pleasant Hill, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Lakeland Regional Cancer Center
Lakeland, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
Joliet Oncology-Hematology Associates
Joliet, Illinois, United States
Michigan State University, Breslin Cancer Center
Lansing, Michigan, United States
Billings Clinic Cancer Research
Billings, Montana, United States
Northshore University Hospital, Monter Cancer Center
Lake Success, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
Cancer Centers of the Carolinas
Greenville, South Carolina, United States
University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
Gunderson Clinic
La Crosse, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

LintuzumabLow dose cytarabinePlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2007
Primary completion: 31 Aug 2010
Completion: 31 Aug 2010
Last update posted: 7 Jan 2015
Registered enrollment: 211
Registry id: NCT00528333

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.